Skip to content

Biohaven BHVN EPS (Diluted)

EPS (Diluted) at other companies

Eli Lilly logo
Eli LillyLLY
$8.26+170%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
-$1.17-41.0%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
-$0.42+38.2%
Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
-$0.85+3.4%
uniQure logo
uniQureQURE
-$0.85-3.7%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$0.05+126%

Other financials

Income statement

See full
Operating income-$130.4M+41.1%
Net income-$130.5M+41.1%

Balance sheet

See full
Cash & equivalents$277.1M+170%
Total debt$286.2M+706%
Total equity$129.5M-50.1%
Total assets$466.4M+1.6%

Cash flow

See full
Operating cash flow-$149.9M+9.2%
CapEx--100%
Free cash flow-$149.9M+9.5%

Valuation

See full
Market cap$2.23B-48.1%
Enterprise value$2.23B-46.3%

Returns & leverage

See full
Return on equity-333%+17.9pp
Debt / equity2.2×+2.1×
Current ratio7.4×+5.1×

Where this comes from

Reported directly by Biohaven in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The official record: Biohaven’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biohaven's eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biohaven's EPS (diluted)?
Biohaven (BHVN) reported EPS (diluted) of -$0.88 in Q1 2026.
How has Biohaven's EPS (diluted) changed year-over-year?
Biohaven's EPS (diluted) increased by 59.4% year-over-year, from -$2.17 to -$0.88.
What is the long-term trend for Biohaven's EPS (diluted)?
Over 3 years (2022 to 2025), Biohaven's EPS (diluted) has grown at a -18.6% compound annual growth rate (CAGR), from -$12.74 to -$6.87.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.